Company Description
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa.
The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.
It also provides PhenoCycler and PhenoImager reagents; and biopharma services.
In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI.
The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Country | United States |
IPO Date | Apr 16, 2021 |
Industry | Medical - Instruments & Supplies |
Sector | Healthcare |
Employees | 330 |
CEO | Brian McKelligon |
Contact Details
Address: 100 Campus Drive Marlborough, Massachusetts United States | |
Website | https://www.akoyabio.com |
Stock Details
Ticker Symbol | AKYA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001711933 |
CUSIP Number | 00974H104 |
ISIN Number | US00974H1041 |
Employer ID | 47-5586242 |
SIC Code | 3826 |
Key Executives
Name | Position |
---|---|
Brian McKelligon | President, Chief Executive Officer & Director |
Dr. Niro Ramachandran Ph.D. | Chief Business Officer |
Dr. Pascal Bamford Ph.D. | Senior Vice President, Research & Development and Laboratory Operations |
Jennifer Kamocsay | General Counsel |
Priyam Shah | Senior Director of Business Development & Investor Relations Strategy |
Rob C. Hart CFA, J.D. | Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 21, 2024 | 4 | Filing |
Nov 21, 2024 | 4 | Filing |
Nov 21, 2024 | 4 | Filing |
Nov 21, 2024 | 4 | Filing |
Nov 21, 2024 | 4 | Filing |
Nov 14, 2024 | 10-Q | Quarterly Report |
Nov 14, 2024 | 8-K | Current Report |
Nov 04, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 04, 2024 | 4 | Filing |
Oct 03, 2024 | 8-K | Current Report |